Skip to main content
ClinicalTrials.govrestricted

One Year Antibody Persistence After a Fourth Dose Boost or Two Catch-Up Doses of Novartis Meningococcal B Recombinant Vaccine Administered Starting From 12 Months of Age and Response to a Third Dose B

ClinicalTrials.gov study NCT01139021. IPD Sharing: Not stated. Countries: 2. Publications: 0.

ShareScore

28/100

Overall dataset sharing score

Score breakdown

These five areas show where the dataset supports — or may limit — practical reuse.

Stewardship
12
Harmonization
8
Access
4
Reuse readiness
0
Engagement
4

Topics